News >

Ibrutinib/Palbociclib Combo Shows Activity in Previously Treated MCL

Darcy Lewis
Published: Thursday, Feb 21, 2019

Dr. Peter Martin

Peter Martin, MD
Combining ibrutinib (Imbruvica) with the CDK4/6 inhibitor palbociclib (Ibrance) appeared to be well tolerated and active in patients with previously treated mantle cell lymphoma, according to phase I data. 1

Results of the dose-finding study showed that, at a median follow-up of 25.6 months, the 2-year progression-free survival (PFS) was 59.4% (95% CI, 37.9-80.9), and the 2-year overall survival (OS) was 60.6% (95% CI, 41.1-80.1). 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication